Greenwich Lifesciences Inc

Stock Chart, Company Information, and Scan Results

$17.21(as of Dec 24, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Greenwich Lifesciences Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$17.21
Ticker SymbolGLSI
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees4
CountyUSA
Market Cap$238.4M

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.

Greenwich Lifesciences Inc In Our Stock Scanner

As of Dec 26, 2025
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.